抑酸药是"致命毒药",会导致癌症、自身免疫性疾病、不孕不育、勃起功能障碍、抑郁、脂肪肝和肠易激综合征;它们自约 2004–2005 年起的普及,解释了癌症和勃起功能障碍的翻倍。
原始表述
خد يا بتاع الجهاز الهضمي اعرف ان مثبطات الحموضه بتجيب امراض مناعيه وسرطان وعقم وارتخى عند الرجاله >> واكتئاب | بص مثبطات الحموضه يا عبد الله في حد ذاتها سم قاتل يعني طالما مثبطات الحموضه بقت موجوده ا اعرف ا ان انت ا المرض جالك حرفيا مناعتك وقعت الام ضهرك ظهرت شعرك وقع عجزت ا عضمك اتاكل اا انسولينك طلع بالرغم ان ان انت ما بتاكلش اصلا هتتخن هتربي كرش
按来源为原话. 译文由本项目提供;以阿拉伯语原文为准。
译文
抑酸药是"致命毒药",会导致癌症、自身免疫性疾病、不孕不育、勃起功能障碍、抑郁、脂肪肝和肠易激综合征;它们自约 2004–2005 年起的普及,解释了癌症和勃起功能障碍的翻倍。
出处
- 来源状态
- 视频转录文本(本人原话)
- 归属
- Elawady (machine transcript)
- 视频
- اتفرجوا عالبودكاست ده وقولولي رأيكوا عشان انزلكوا الحلقه التانيه منه (打开来源)
- 发布日期
- 2026年4月9日
- 时间戳
- 无(转录文本不含时间信息)
- 归属的不确定性
- Podcast/live-stream machine transcript. In 6T7S4CEKswY the word 'depression' follows a speaker change (>>) and may have been added by the interviewer and affirmed by Elawady. original_ar joins separate verbatim passages with ' | '.
- 所声称的机制
Not specified; general toxicity of acid suppression.
- 所声称的健康影响
Cancer, autoimmune disease, infertility, ED, depression, fatty liver, IBS.
- 涉及人群
All users.
- Elawady 设定的地域限制
none found
来源版本存在差异
بص مثبطات الحموضه يا عبد الله في حد ذاتها سم قاتل يعني طالما مثبطات الحموضه بقت موجوده ا اعرف ا ان انت ا المرض جالك حرفيا مناعتك وقعت الام ضهرك ظهرت شعرك وقع عجزت ا عضمك اتاكل اا انسولينك طلع بالرغم ان ان انت ما بتاكلش اصلا هتتخن هتربي كرش
- 来源状态
- 视频转录文本(本人原话)
- 归属
- Elawady (machine transcript)
- 视频
- بدأت قناة "Dr Diaa Al Awady د ضياء العوضي" بثًا مباشرًا لايف حلو (打开来源)
- 发布日期
- 2026年3月29日
- 时间戳
- 0:11:45 (在原视频 YouTube 自动字幕轨中的位置;可确认该内容出现的位置,但不能确认说话人是谁)
يعني انا كونترلوك قلت عليه بدل المره 1000 مره بيجيب سرطانات وامراض مناعيه
- 来源状态
- 视频转录文本(本人原话)
- 归属
- Elawady (machine transcript)
- 视频
- زرع الكلي : الحمد لله مناقشة حرة (打开来源)
- 发布日期
- 2025年2月16日
- 时间戳
- 0:36:50 (在原视频 YouTube 自动字幕轨中的位置;可确认该内容出现的位置,但不能确认说话人是谁)
انا في 2004 حضرت مثبطات المناعه اللي هي النهارده برشام بقى عادي اللي هو مثبطات الحموضه الكونترولوك والنكسيام والحاجات والبيبلوك والبيبتيوك وكل اللوك ده اللي هو بينزلوها دلوقتي من غير روشته ولا اي حاجه الدوا ده 2004 ما كانش عارف يدخل البلد ولا عارف يمشي فبقوا يجولنا احنا في الرعايه شغلوه بدا وحطوه بدل الزنتاك الزنتاج ده برض حاجه شبهه بس كان اقل فعاليه لان هو ما كانش بيقفل الحمض قوي بس ومع ذلك كانوا يكتبوا في الروشي بتاعته بيجيب اضطرابات هرمونيه ما كانش حد فاهم ليه بياثر على الذكوره بيقلل الرغبه الجنسيه ده فين ده في نشط الزنتان طب ايه اختلاف الزنتاك عن الكونترلاك او عند النكسيم اهو نفس الفكره انا هقفل حمض المعده بقى يبقى الموضوع لازم تربطه لي بحاجه اقول لك لا لا اصل المولكيول ده غير ده اصل الميكانزم ده غير ده يا باشا الاند الاند ريزلت انا بقفل الحمض فسنه 2004 اما تيجي تحسبها دلوقتي 2026 شوف في ال 20 سنه 22 سنه تضاعف حالات السرطان وضعف الانتصاب وسرطانات البروستاتا
- 来源状态
- 视频转录文本(本人原话)
- 归属
- Elawady (machine transcript)
- 视频
- بودكاست قبل رمضان (打开来源)
- 发布日期
- 2026年2月17日
- 时间戳
- 0:52:55 (在原视频 YouTube 自动字幕轨中的位置;可确认该内容出现的位置,但不能确认说话人是谁)
مع وجود مثبطات الحموضه التي طرحت في الاصوات يعني في حدود ال عاما من 2005 اطرحت اسواق البي بي ايز بدء من الكونترول الجد فاذر والجاي ورا لا يجب اهمالله ومع وجود تطور للمرض وظهور السرطانات لا يجب تجاهل دور مثبطات الحموضه في ظهور هذه الاعراض
- 来源状态
- 视频转录文本(本人原话)
- 归属
- Elawady (machine transcript)
- 视频
- بيان فلسفه النظريه (打开来源)
- 发布日期
- 2026年2月14日
- 时间戳
- 0:06:12 (在原视频 YouTube 自动字幕轨中的位置;可确认该内容出现的位置,但不能确认说话人是谁)
أدوية مثبطات الحموضة ممنوعة عندي بشكل دائم — هي سموم تسبب الكبد الدهني والقولون العصبي، وتمنع الجسم من الاستفادة من الطعام وامتصاص الحديد وفيتامين ب12 والمعادن، وتعالج الأعراض فقط بينما تفاقم المشاكل الأساسية من نمو بكتيري وسوء هضم.
- 来源状态
- 档案网站引语(未注明出处)
- 归属
- Elawady (archive paraphrase; source video not given)
- 出处
- https://eltayebat.com/rule/acid-blockers/
科学评估
基本错误 – 该说法的主要部分没有证据支持,或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么?
Acid blockers are poison and cause cancer, autoimmune disease, infertility, ED, depression, fatty liver and IBS.
2. 哪些内容可证实是正确的?
Some cohort studies report associations of long-term PPI use with gastric cancer (Cheung 2018: HR 2.44 after H. pylori eradication; Abrahami 2022: HR 1.45 versus H2 blockers, I-PPI-108) and dementia (Gomm 2016: HR 1.44); PPIs are overused (see C-PPI-11).
3. 哪些内容是错误或夸大的?
'Deadly poison' and the list of diseases are not supported. The gastric cancer signal is small in absolute terms (about 1 extra case per 1,200-2,100 users over 5-10 years in I-PPI-108) and partly explained by protopathic bias (I-PPI-107); the dementia signal was not confirmed by the COMPASS RCT. No evidence was found for infertility (semen quality unaffected, I-PPI-109), erectile dysfunction, depression, fatty liver or autoimmune disease as PPI effects. Rising cancer or ED figures since 2004 are an ecological correlation without causal value.
4. 哪些内容仍不明确?
Long-term (>10 years) effects on gastric cancer in specific groups remain under study.
5. 哪些研究支持该说法?
A-PPI-11 (gastric cancer association), A-PPI-04 (dementia association), I-PPI-108 (gastric cancer HR 1.45 vs H2RA, small absolute risk).
6. 哪些研究与该说法相矛盾?
COMPASS (I-PPI-01): no significant differences for cancer, dementia and other outcomes except enteric infections. Sawaid 2026 (I-PPI-107): no excess upper GI cancer with long-term use after handling protopathic bias. Keihani 2018 (I-PPI-109): no association with semen quality.
7. 对德国和欧洲而言情况如何?
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
8. 关于埃及的已知情况是什么?
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
9. 合理的实际结论是什么?
出于对这些疾病的恐惧而停用有适应证的 PPI,没有证据支持,而且可能有害(参见 C-PPI-10)。
评估详情
- 证据确定性的依据
The best active-comparator cohort found a gastric cancer HR of 1.45 versus H2RAs with a very small absolute excess (number needed to harm 2121 at 5 years and 1191 at 10 years; I-PPI-108). A 2026 case-control study showed that upper GI cancer associations are concentrated in the months before diagnosis and disappear after accounting for symptoms that lead to PPI prescriptions (protopathic bias; I-PPI-107). The COMPASS RCT found no excess of cancer or other outcomes except enteric infections over 3 years (I-PPI-01). For infertility, the only identified study found no effect on semen quality (I-PPI-109); for erectile dysfunction, depression, autoimmune disease and fatty liver no adequate evidence was found. Ecological trends since 2004 cannot separate PPIs from ageing, diagnosis and other changes.
- 来源质量
Video statements; no studies cited by Elawady for these outcomes.
- 地区可推广性
Not region-specific.
- 个体例外情况
None identified.
- 说法的地域范围
- 普遍性(生物学/医学)
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反,或该说法与已确立的生理学知识相矛盾。
研究问题: Are acid blockers 'deadly poison' that cause cancers, autoimmune diseases, infertility, erectile dysfunction, depression, fatty liver and IBS, explaining rising rates since 2004-2005?
研究问题详解 (PECO)
- 人群
- PPI users
- 干预或暴露
- PPI use
- 对照
- H2RA use / non-use / placebo
- 地域范围
- universal pharmacology
- 结局指标
- Cancer (gastric, upper GI)
- Other listed diseases
- Mortality
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法?
Long-term PPI use linked with a small rise in stomach cancer
UK active-comparator cohort: PPI associated with gastric cancer vs H2RA, with dose-response.
- 实际结果
- HR 1.45 (1.06-1.98); NNH 2121 (5 y), 1191 (10 y)
- 方法学质量
- moderate
- 相关性
- direct for gastric cancer only
- 局限
- Observational; H. pylori incompletely captured
PPIs and stomach cancer after H. pylori treatment
Hong Kong cohort after H. pylori eradication: long-term PPI associated with gastric cancer.
- 实际结果
- HR 2.44 (packet)
- 方法学质量
- moderate
- 相关性
- direct, specific population
- 局限
- Observational
哪些证据不支持该说法?
Pantoprazole safety in a large randomised trial
Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056 随机对照试验全文,含结构化偏倚风险评估COMPASS RCT: no excess cancer, dementia or other outcomes except enteric infections.
- 实际结果
- As in packet
- 方法学质量
- high
- 相关性
- direct (3 years)
- 局限
- 3 years
PPI-cancer link largely reflects early cancer symptoms
Israeli case-control: cancer associations confined to months before diagnosis (protopathic bias); none with long-term use after adjustment.
- 实际结果
- aOR 4.01 recent -> no excess >1 year before diagnosis; remote omeprazole 0.62
- 方法学质量
- moderate (full text)
- 相关性
- direct
- 局限
- Observational
No link between PPIs and sperm quality
Fertility-clinic cohort: no association of PPI use with semen quality.
- 实际结果
- No significant differences (248 users)
- 方法学质量
- low
- 相关性
- direct for fertility claim
- 局限
- Weak design
总体证据说明了什么?
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持?
Apart from a small, uncertain gastric cancer signal, the listed harms are not supported; 'deadly poison' and an explanation of population-wide disease trends are incompatible with randomised and absolute-risk data.
为什么有些研究权重更大
RCT and bias-controlled observational data outweigh crude associations; ecological trend arguments have no causal value.
因果关系是否已确立? 尚未确立 Gastric cancer: possible small effect; other listed diseases: no evidence identified (infertility contradicted weakly; ED, depression, autoimmune disease, fatty liver: no good studies found).
仍存在的不确定性
Long-term (>10 years) gastric cancer risk in H. pylori-exposed people.
合理的结论
Mostly false.
为什么研究结果看起来互相矛盾?
Abrahami (HR 1.45) vs Sawaid (no excess after handling protopathic bias): differ in comparator (H2RA vs non-users), exposure timing and adjustment for symptom diagnoses.
这是否取决于国家?
- 一般生物学效应
- Pharmacology of PPIs is the same in Egypt and Europe.
- 饮食习惯
- Not decisive.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant (except ranitidine NDMA impurities, C-PPI-08).
- 本国生产条件
- Generic products are used in both regions; no evidence of different pharmacological effects.
- 法律规则
- PPIs are partly available without prescription in Egypt and (small packs, short-term) in the EU; prescribing practices differ.
- 实际监测数据
- No Egyptian outcome data identified; one Egypt/Iraq pharmacist survey (I-PPI-120).
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Absolute excess from NNH – 47 per 100,000 at 5 y; 84 per 100,000 at 10 y 已重新计算
- Log-symmetry and protopathic pattern – Recent aOR 4.01 (3.20-5.03) vs remote 0.62 (0.51-0.75) consistent CIs; pattern of reverse causation 已重新计算
总体证据的确定性(GRADE,简化版)
- 主要结局
- Cancer and other serious disease caused by PPIs
- 起始等级
- 高(随机试验)
- 降级理由
- imprecision (3-year RCT)
- indirectness for long-term cancer
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估;并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据,而非单项研究。
已核查的临床指南和官方声明
- AGA (American Gastroenterological Association): AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review (Targownik LE et al., Gastroenterology 2022; I-PPI-04) (2022) · 原始文献
Best Practice Advice read verbatim in the PubMed record: regular review and documentation of the indication (BPA 1); trial of de-prescribing for all without a definitive indication (BPA 2); complicated GERD (severe erosive oesophagitis, oesophageal ulcer, peptic stricture) generally not for discontinuation (BPA 4); Barrett's oesophagus, eosinophilic oesophagitis, idiopathic pulmonary fibrosis generally not for de-prescribing (BPA 5); assess upper GI bleeding risk first and do not de-prescribe in high-risk patients (BPA 6-7); warn about transient rebound symptoms (BPA 8); tapering or abrupt stop both possible (BPA 9); decide on indication, not on fear of PPI-associated adverse events (BPA 10). The publisher page could not be fetched (HTTP 403). - NICE: Suspected cancer: recognition and referral (NG12), upper GI section (I-GUT-109) (2015, page updated April 2026) · 原始文献
Suspected cancer pathway referral for dysphagia, or age 55+ with weight loss plus upper abdominal pain, reflux or dyspepsia; consider endoscopy for haematemesis and for age 55+ with treatment-resistant dyspepsia or upper abdominal pain with low haemoglobin. - ACG (American College of Gastroenterology): ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO et al. 2022; I-PPI-10) (2022) · 原始文献
Full text read: weight loss recommended for overweight/obese patients (strong, moderate evidence); avoid meals within 2-3 h of bedtime, avoid tobacco, avoid 'trigger foods', elevate head of bed for nocturnal symptoms (conditional, low evidence); Table 3 rates 'avoid carbonated beverages' as moderate evidence and recommendable; PPIs over H2RAs for healing erosive oesophagitis (strong, high evidence); attempt to discontinue PPIs in patients without erosive oesophagitis or Barrett's whose symptoms resolved (conditional, low); maintenance PPI indefinitely or surgery for LA grade C/D oesophagitis (strong, moderate); endoscopy first for dysphagia or alarm symptoms (weight loss, GI bleeding); rebound shown in healthy controls but strong evidence for symptom increase after abrupt withdrawal in patients is lacking.
检索策略
本次审查的文献检索记录(检索式采用原数据库语法)。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:("proton pump inhibitor*") AND TITLE:"gastric cancer" AND (cohort OR "meta-analysis") AND PUB_YEAR:[2019 TO 2026] | 支持性证据 | 14 | |
| Europe PMC | 2026年10月26日 | TITLE:("proton pump inhibitor*") AND TITLE:(cancer) AND ("active comparator" OR "histamine-2" OR "H2RA") AND PUB_YEAR:[2019 TO 2026] | 双向 | 11 | |
| Europe PMC | 2026年10月26日 | AUTH:"Abrahami D" AND TITLE:"gastric cancer" | 支持性证据 | 1 | |
| Europe PMC | 2026年10月26日 | TITLE:("proton pump inhibitor*") AND TITLE:(depression OR "erectile" OR infertility OR "autoimmune" OR "fatty liver" OR NAFLD OR "semen") | 支持性证据 | 15 | |
| PubMed (E-utilities esearch) | 2026年10月26日 | (proton pump inhibitors[mh]) AND (neoplasms[mh] OR depression[mh] OR erectile dysfunction[mh] OR infertility[mh] OR autoimmune diseases[mh]) AND (meta-analysis[pt] OR cohort[tiab]) AND 2020:2026[dp] | 双向 | 186 | |
| PubMed efetch (record of PMID 35183361) | 2026年10月26日 | efetch id=35183361 (AGA 2022 de-prescribing BPA statements); publisher page attempted via WebFetch returned HTTP 403 | 指南 | 1 | |
| Web (curl/WebFetch of guideline page) | 2026年10月26日 | https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer | 指南 | 1 |
待解决的问题
Data on erectile dysfunction, depression, autoimmune disease and fatty liver with appropriate designs.
核查深度如何?
6 项相关研究:2 项核查了全文(其中 1 项进行了结构化偏倚风险评估),4 项基于摘要核查,0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估,也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (低)
- 2026年10月26日 · 第 4 阶段(系统证据审查) · 评定结论已更改: 基本错误 (低) → 基本错误 (中)
Certainty raised: absolute-risk data from the best active-comparator cohort and a study demonstrating protopathic bias now quantify the cancer signal as small and partly artefactual; with the RCT this gives moderate certainty that the sweeping claim is mostly false.
新来源: I-PPI-107 I-PPI-108 I-PPI-109
通俗解释
一些研究发现,长期使用抑酸药的人更常患胃癌,但额外风险很小(在一项研究中,一千多名使用者在多年间约多出一例),而且其中一部分来自人们因尚未确诊的癌症症状而开始服药。一项大型随机对照试验在三年中没有发现癌症或痴呆增多。没有良好证据表明 PPI 会导致不孕不育、阳痿、抑郁、脂肪肝或自身免疫性疾病,称其为致命毒药是不准确的。停用可预防出血的 PPI 可能是危险的。
与该说法相关的研究
支持该说法的研究 (1)
-
PPIs and stomach cancer after H. pylori treatment
Cheung KS et al.. Gut 2018 · PMID 29089382 · DOI 10.1136/gutjnl-2017-314605队列研究被 Tayebat 档案网站引用已核查摘要★ 关键研究Long-term PPI use was linked to more gastric cancer, about 4 extra cases per 10,000 person-years.
该研究是否支持这一具体说法? 部分支持 · 方法学质量: 中 · 证据确定性:见该说法的总体评估
研究通俗解读
- 研究人员想了解什么?
GC after eradication.
- 研究是如何开展的?
Cohort with propensity scores.
- 研究了多少人、动物或样本?
63,397.
- 实际发现了什么?
Association, duration gradient.
- 观察到的效应有多大?
HR 2.44; ARD 4.29/10,000 py.
- 研究结果对日常生活意味着什么?
Small absolute excess.
- 该研究有哪些局限?
Few events; confounding.
- 它对 Elawady 的具体说法说明了什么?
Partly supports cancer claim for gastric cancer only.
- 研究结果是否适用于德国和欧洲?
Moderate.
- 从该研究中明确不能得出什么结论?
Causation; other cancers.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (3)
-
Pantoprazole safety in a large randomised trial
Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056随机对照试验独立交叉核查全文,含结构化偏倚风险评估★ 关键研究Over three years, only gut infections were more common with pantoprazole (1.4% vs 1.0%).
该研究是否支持这一具体说法? 否 · 方法学质量: 高 · 证据确定性:见该说法的总体评估
研究通俗解读
- 研究人员想了解什么?
Test PPI harms in an RCT.
- 研究是如何开展的?
Placebo-controlled trial.
- 研究了多少人、动物或样本?
17,598 heart/vascular patients.
- 实际发现了什么?
No excess harm except enteric infections.
- 观察到的效应有多大?
OR 1.33 enteric infections.
- 研究结果对日常生活意味着什么?
PPIs are largely safe for 3 years.
- 该研究有哪些局限?
3-year duration; specific population.
- 它对 Elawady 的具体说法说明了什么?
Contradicts most broad harm claims; supports infection risk.
- 研究结果是否适用于德国和欧洲?
Applicable.
- 从该研究中明确不能得出什么结论?
Very long-term effects.
-
PPI-cancer link largely reflects early cancer symptoms
Sawaid IO et al.. PLoS Med 2026 · PMID 41493925 · DOI 10.1371/journal.pmed.1004842病例对照研究独立交叉核查已核查全文★ 关键研究People often start acid blockers because of symptoms of a still-undiagnosed cancer; after accounting for this, long-term PPI use was not linked to more upper GI cancer.
Cancer association explained by protopathic bias; no excess with long-term use
该研究是否支持这一具体说法? 否 · 方法学质量: 中 · 证据确定性:见该说法的总体评估
研究通俗解读
- 研究人员想了解什么?
Re-examine PPIs and upper GI cancer.
- 研究是如何开展的?
Matched case-control, 875 cases.
- 研究了多少人、动物或样本?
Israeli health records, incl. Arab citizens.
- 实际发现了什么?
Strong recent-use link vanished for earlier use.
- 观察到的效应有多大?
aOR 4.01 recent esomeprazole; 0.62 remote omeprazole.
- 研究结果对日常生活意味着什么?
Alarm symptoms should be investigated, not blamed on the medicine.
- 该研究有哪些局限?
Observational; OTC use missed.
- 它对 Elawady 的具体说法说明了什么?
Contradicts 'PPIs cause cancer'.
- 研究结果是否适用于德国和欧洲?
Moderately applicable.
- 从该研究中明确不能得出什么结论?
Cannot exclude effects after >10 years.
-
No link between PPIs and sperm quality
Keihani S et al.. Asian J Androl 2018 · PMID 28879865 · DOI 10.4103/aja.aja_35_17队列研究独立交叉核查已核查摘要Among men at a fertility clinic, those taking PPIs had similar semen results to men taking no medicines.
No association of PPI use with semen quality
该研究是否支持这一具体说法? 否 · 方法学质量: 低 · 证据确定性:见该说法的总体评估
研究通俗解读
- 研究人员想了解什么?
Check PPIs and semen quality.
- 研究是如何开展的?
Retrospective cohort.
- 研究了多少人、动物或样本?
248 PPI users, 7698 controls.
- 实际发现了什么?
No significant differences.
- 观察到的效应有多大?
Not significant.
- 研究结果对日常生活意味着什么?
No sign that PPIs harm sperm.
- 该研究有哪些局限?
Weak design.
- 它对 Elawady 的具体说法说明了什么?
Contradicts infertility claim (weakly).
- 研究结果是否适用于德国和欧洲?
Applicable.
- 从该研究中明确不能得出什么结论?
Cannot exclude small effects.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (2)
-
PPIs and dementia in German claims data
Gomm W et al.. JAMA Neurol 2016 · PMID 26882076 · DOI 10.1001/jamaneurol.2015.4791队列研究被 Tayebat 档案网站引用已核查摘要Regular PPI users were diagnosed with dementia 1.44 times as often.
该研究是否支持这一具体说法? 不明确 · 方法学质量: 低 · 证据确定性:见该说法的总体评估
研究通俗解读
- 研究人员想了解什么?
Dementia risk with PPIs.
- 研究是如何开展的?
Insurance claims analysis.
- 研究了多少人、动物或样本?
73,679 people ≥75 years.
- 实际发现了什么?
Association with dementia.
- 观察到的效应有多大?
HR 1.44.
- 研究结果对日常生活意味着什么?
Not proof of harm.
- 该研究有哪些局限?
Claims data; confounding.
- 它对 Elawady 的具体说法说明了什么?
Not directly used by archive.
- 研究结果是否适用于德国和欧洲?
German data.
- 从该研究中明确不能得出什么结论?
Causation.
-
Long-term PPI use linked with a small rise in stomach cancer
Abrahami D et al.. Gut 2022 · PMID 34226290 · DOI 10.1136/gutjnl-2021-325097队列研究独立交叉核查已核查摘要★ 关键研究Compared with H2 blockers, PPI users had a 45% higher relative risk of stomach cancer, but only about 1 extra case per 1,200-2,100 users over 5-10 years.
Gastric cancer HR 1.45 vs H2RA; absolute excess ~1 per 1000-2000 users
该研究是否支持这一具体说法? 部分支持 · 方法学质量: 中 · 证据确定性:见该说法的总体评估
研究通俗解读
- 研究人员想了解什么?
Compare stomach cancer risk of PPI and H2RA users.
- 研究是如何开展的?
Large UK cohort.
- 研究了多少人、动物或样本?
Over 1.1 million new users.
- 实际发现了什么?
HR 1.45; dose-response.
- 观察到的效应有多大?
NNH 2121 (5 y), 1191 (10 y).
- 研究结果对日常生活意味着什么?
If real, the extra risk is small; use PPIs only when indicated.
- 该研究有哪些局限?
Observational; H. pylori not fully known.
- 它对 Elawady 的具体说法说明了什么?
Partly supports a cancer concern; contradicts 'deadly poison'.
- 研究结果是否适用于德国和欧洲?
UK data, applicable to Europe.
- 从该研究中明确不能得出什么结论?
Cannot prove causation.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
埃及
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
在我的国家适用什么?
一般科学评估
基本错误 基本错误:除了一个微弱且不确定的胃癌信号外,所列的危害都缺乏依据,"致命毒药"的说法是错误的。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用;各国食品数据不会改变这一评估。
参考文献
- Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study.. Cheung KS et al.. Gut 2018 · PMID 29089382 · DOI 10.1136/gutjnl-2017-314605
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
- Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication.. Sawaid IO et al.. PLoS Med 2026 · PMID 41493925 · DOI 10.1371/journal.pmed.1004842
- Proton-pump inhibitor use does not affect semen quality in subfertile men.. Keihani S et al.. Asian J Androl 2018 · PMID 28879865 · DOI 10.4103/aja.aja_35_17
- Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.. Gomm W et al.. JAMA Neurol 2016 · PMID 26882076 · DOI 10.1001/jamaneurol.2015.4791
- Proton pump inhibitors and risk of gastric cancer: population-based cohort study.. Abrahami D et al.. Gut 2022 · PMID 34226290 · DOI 10.1136/gutjnl-2021-325097